Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors

Category Primary study
JournalJournal of Clinical Oncology
Year 2012
This article has no abstract
Epistemonikos ID: 45fcebee88bc491db9b2f309003f30a0932da6ac
First added on: Feb 05, 2025